Bibliography
- Tyler DS. Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother 2009;11(1):79-93
- Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47
- Beasley GM, Caudle A, Petersen RP, A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009;208:706-15; discussion 15-7
- McMahon N, Cheng TY, Beasley GM, Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009;16:953-61
- Santillan A, Delman KA, Beasley GM, Prognostic factors of regional and systemic toxicity after isolated limb infusion (ILI): a multi-institutional analysis. Ann Surg Oncol 2009;16:2570-8
- Beasley GM, McMahon N, Sanders G, A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 2009. [Epub 27 Jul 2009]
- Gallagher SJ, Thompson JF, Indsto J, p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors. Neoplasia 2008;10:1231-9
- Beasley GM, Petersen RP, Yoo J, Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15:2195-205